Nearly all children get sick from respiratory syncytial virus, or RSV, by the age of 2, and last year, there was a notable surge in RSV-associated hospitalizations. But the Food and Drug Administration is now considering approval of a vaccine and a monoclonal antibody aimed at protecting infants from this common virus.
This year, the Food and Drug Administration will consider several applications for vaccines and a monoclonal antibody to prevent respiratory syncytial virus, or RSV, illness. We’ll go through some common questions about RSV and the potential vaccines for older adults in this story.
Retooled COVID-19 booster vaccines that target omicron subvariants of the coronavirus are now available in the U.S. Here, we answer questions about the new shots.
After a long delay marred by manufacturing troubles, a COVID-19 vaccine from Novavax became the fourth such vaccine authorized in the U.S. We review how it works and how it’s different from its competitors.
In this story, we’ll explain what we know about the financial and conflict-of-interest disclosure requirements for Dr. Anthony Fauci, other National Institutes of Health higher-ups and members of two U.S. vaccine advisory committees.
Children under 5, including those as young as 6 months of age, are now able to be vaccinated against COVID-19. Here, we explain what’s known about the two coronavirus vaccines for the youngest children.
Despite persistent claims to the contrary, none of the three authorized or approved COVID-19 vaccines contains fetal tissue. We take a look at the facts in light of Justice Clarence Thomas’ dissent.
Once scarce, Paxlovid, an antiviral pill that is the preferred treatment for non-hospitalized high-risk COVID-19 patients, is no longer in such short supply. Here, we explain what the drug does, how well it works and what questions remain.
What does a fact-checking organization do when the facts aren’t clear? And what happens when reputable scientists disagree about a public health policy?
At the end of March, the Food and Drug Administration authorized a second COVID-19 booster dose for people 50 years of age and older. But the data supporting the extra shot is limited. Here, we break down the available evidence and share what scientists recommend.